J&J looks to bolster cardiology devices segment

Growth in the segment has stunted over the past few years, prompting the new CEO to look at acquisitions.

By Trefis May 16, 2012 10:19AM
TrefisIt was not long ago that Johnson & Johnson (JNJ) bought orthopedic manufacturer Synthes. Now, the pharmaceutical giant is looking at more such acquisitions, especially for its cardiology devices business that has taken a beating over the past few years.

J&J operates in three important segments: consumer, pharmaceuticals, and diagnostics. It competes with Pfizer (PFE), Merck (MRK) and Abbott Labs (ABT).

We maintain a $72.45 price estimate for JNJ, which is nearly 10% above the current market price, largely based on our long-term outlook for the company.

JNJ Market Share of Vision Care, Diabetes and Other Medical Devices

According to our estimates, J&J's market share in stents, catheters and other medical devices will stagnate over our forecast period. This is largely due to discouraging results from its cardiovascular devices segment in the past five years.


However, newly appointed CEO Alex Gorsky is looking at acquisitions to reinvigorate the segment with products such as heart valves. The possible takeover targets are Edwards Lifesciences (EW) and St. Jude Medical (STJ), according to Bloomberg.


Edwards Lifesciences holds half of the heart valves market, while St. Jude enjoys the highest operating margins in the industry. Some of J&J's products have performed miserably in terms of quality. Several over-the-counter products of the company were recalled because of foul odors and adulterated ingredients.


We expect these acquisitions will help J&J gain market share in cardiology devices. Stents, catheters and other medical devices account for 18% of Trefis price estimate for JNJ stock, by our analysis.


More from Trefis:

Tags: EWJNJSTJ
0Comments

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

STOCK SCOUTER

StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

123
123 rated 1
262
262 rated 2
480
480 rated 3
651
651 rated 4
649
649 rated 5
629
629 rated 6
616
616 rated 7
496
496 rated 8
346
346 rated 9
111
111 rated 10
12345678910

Top Picks

SYMBOLNAMERATING
EXCEXELON CORPORATION9
TAT&T Inc9
VZVERIZON COMMUNICATIONS8
CTLCENTURYLINK Inc8
AAPLAPPLE Inc10
More

VIDEO ON MSN MONEY

ABOUT

Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.